PatientsVille.com Logo


Exposure To Communicable Disease Medical Research Studies

Up-to-date List of Exposure To Communicable Disease Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Exposure To Communicable Disease Medical Research Studies

Rank Status Study
1 Recruiting On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
Condition: HIV Infection
Interventions: Drug: Truvada;   Drug: Placebo
Outcome Measures: Contamination with HIV-1 or -2;   Evolution of sexual behavior and potential at-risk behavior;   Incidence of clinical and biological adverse events;   Treatment adherence;   Incidence of hepatitis B;   Incidence of other sexually transmitted diseases;   Frequency of HIV resistance to antiretrovirals in HIV infected subjects;   Emtricitabine and tenofovir concentrations in plasma, saliva and rectal samples.;   Costs evaluation
2 Unknown  A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection
Conditions: Infection;   HIV
Intervention: Drug: Truvada and Isentress
Outcome Measures: Safety;   HIV seroincidence
3 Recruiting Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
Conditions: Occupational Accidents;   Incubation Period, Infectious Disese
Outcome Measure:
4 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
Outcome Measures: Toxicity endpoint: Adverse events (AEs) of Grade 3 or 4 severity;   Toxicity endpoint: death;   Toxicity endpoint: Suspected adverse drug reaction (SADR) of Grade 3 or 4 severity;   PK endpoint for Cohort 1: maximum concentration (Cmax) of RAL;   PK endpoint for Cohort 1: area under the concentration-time curve at the 12-hour dosing internal (AUC12) of RAL;   PK endpoint for once-daily dosing in Cohort 2: area under the concentration-time curve at the 24-hour dosing internal (AUC24);   PK endpoint for twice-daily dosing in Cohort 2: AUC12;   PK endpoint for Cohort 2: geometric mean (GM) trough;   Toxicity endpoint: AEs of Grade 3 or 4 severity;   SADR of Grade 3 or 4 severity;   Death
5 Unknown  Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
Condition: HIV Infections
Interventions: Drug: raltegravir (Isentress);   Drug: Truvada®
Outcome Measure: To assess the nature and incidence of drug intolerance and to compare the results with those of previous studies conducted according to the same methodology, with other combinations of antiretrovirals.
6 Recruiting Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries
Condition: Surgical Wound Infection
Intervention: Behavioral: Early Water Exposure
Outcome Measures: Post-operative wound infection;   Incidence of post-operative bleeding complications;   Scar appearance;   Quality of Life
7 Not yet recruiting An Open Label, Phase IV Study Evaluating the Clinical Benefit, Safety and Pharmacokinetics of Raxibacumab in Subjects Exposed to Bacillus Anthracis
Condition: Infections, Bacterial
Intervention: Other: Collection of samples
Outcome Measures: Clinical benefit as assessed by overall survival to week 24 for cohort 1;   Clinical benefit as assessed by emergence rate of systemic anthrax infection to week 24 for Cohort 2;   Clinical benefit as assessed by rate of resolution of edema and healing of lesion without emergence of systemic anthrax infection to week 24 for cohort 3;   Survival rate on Day 14 and Day 28;   Length of (Intensive Care Unit) ICU stay;   Incidence of associated complication of anthrax (meningitis, pleural effusion);   Incidence of the progression of the disease clinical stage for subject in Cohort 1;   Incidence of the progression to systemic anthrax infection for subjects in Cohorts 2 and 3;   Summary of the area of wound/lesions for subjects in Cohort 3;   Summary of significant concurrent medical treatment;   Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs);   Summary of  ECG data;   Summary of Vital Signs;   Summary of serum raxibacumab concentrations;   Summary of disease markers: Protective Antigen (PA), toxin neutralizing antibody (TNA) and Anti-drug antibody (ADA) levels;   Length of hospital stay;   Summary of neurological function as assessed by Glasgow Coma Scale or Adelaide Pediatric Scale;   Summary of daily functionality as assessed by Katz ADL;   Incidence of bacteremia;   Summary of clinical chemistry and hematology laboratory data
8 Recruiting Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions: Infection;   Hypertension;   Anesthesia;   Pain;   Reflux;   Nausea;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma
Intervention: Drug: Ampicillin
Outcome Measures: Composite of pharmacokinetic outcomes for understudied drugs in children;   Composite pharmacodynamic outcomes of understudied drugs in children;   Biomarkers associated with understudied drugs in children
9 Recruiting RSV Observational Study 2
Condition: Respiratory Syncytial Virus Infections
Intervention: Procedure: Blood sample
Outcome Measure: To assess the induction of RSV-specific immune responses in blood following natural exposure
10 Recruiting Evaluating the Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents
Condition: HIV Infections
Intervention: Drug: Truvada
Outcome Measures: The proportion of participants who report willingness to use the study regimen, take up PrEP, and remain on PrEP as part of a comprehensive prevention package;   Assessment of acceptability as per questionnaire administered at study end;   Number of adolescents who continue to use PrEP (as indicated by dried blood spot [DBS] levels) after the initial 3-month period;   The total time on PrEP (as indicated by DBS levels) for each adolescent who indicated PrEP use by self-report at the beginning of each 3-month period;   The total time on PrEP (as indicated by DBS levels) for the cohort as a whole in those individuals who indicated PrEP use by self-report at the beginning of each 3-month period;   Assessment of Grades 2, 3, and 4 clinical and laboratory adverse events;   Number of adolescents recruited, enrolled, and retained in the study;   Assessment of adherence to daily regimens of oral PrEP as evidenced by the use of self-report, pill counts, and proportion of participants on Truvada who have detectable drug levels;   Proportion of blood samples with detectable drug levels;   Proportion of adolescents with detectable drug levels who report using PrEP;   Proportion of doses that are taken as instructed;   Reported number of steady and casual sex partners as evidenced by participant responses to interviewer-administered questionnaires and focus groups;   Reported condom use (and change after introduction of study product) as evidenced by participant responses to interviewer-administered questionnaires and focus groups;   Reported substance use prior to or during sex as evidenced by participant responses to interviewer-administered questionnaires and focus groups;   Proportion of scheduled HIV testing appointments missed, in relation to individual characteristics (age, sex, number of partners, use of other prevention methods) and the characteristics of the product;   Frequency of HIV infection as measured by seroconversion of study participants during the approximate 12 months of follow up
11 Not yet recruiting Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers
Condition: Influenza
Interventions: Other: Questionnaire;   Other: Blood sample;   Other: Nasal wash;   Other: Throat swab
Outcome Measures: Incidence of avian influenza (AI) in poultry-exposed populations;   Sero-prevalence rates of infection with AI viruses;   Risk factors associated with AI human infections in poultry-exposed individuals;   Secondary infection risk for household contacts;   Antigenic and genetic makeup of AI viruses infecting humans;   Pathogenicity and disease severity of AI viruses causing human infections and the associated immune response;   Serologic response following confirmed influenza virus infection
12 Recruiting PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: Tenofovir/emtricitabine
Outcome Measures: Participants' self-reported overall acceptability of PrEP;   The level of community interest in PrEP;   Adherence to daily TDF/FTC-based PrEP;   Time required by the patient, physician and research coordinator for each type of study visit.;   HIV infection;   Sexually transmitted infections;   Burden of syndemic health problems;   Change in estimated glomerular filtration rate;   Percentage change in bone mineral density at the lumbar spine and total hip;   Adverse events;   Pilot testing study instruments
13 Unknown  Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
Conditions: HIV Transmission;   HIV Infections
Intervention: Drug: tenofovir + emtricitabine, lopinavir/ritonavir
Outcome Measures: To provide a comprehensive package of HIV prevention services, of which PEP can be an integral component.;   To evaluate the acceptability, feasibility, and safety of administering PEP in easily acceptable, non-judgmental, culturally, ethnically and linguistically appropriate environments.
14 Recruiting Aerosolized and Intravenous Colistin in Healthy Adults
Conditions: Pneumonia;   Pneumococcal Infection;   Pathogen Resistance
Intervention: Drug: Colistimethate sodium
Outcome Measures: The occurrence of intravenous and aerosolized colistimethate sodium by serial assessment of solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing (hematology, chemistries, urinalysis), & ECG changes.;   Pharmacokinetics: measure of plasma colistimethate sodium, colistin A, and colistin B levels at multiple time points. Parameters: Cmax, AUC 0-t, Tmax, T1/2, Kel, clearance. Cohorts 1-4.;   Pharmacokinetics: measure of plasma colistimethate sodium, colistin A, and colistin B levels at multiple time points. Parameters: Cmax, AUC 0-t, Tmax, T1/2, Kel, clearance. Cohort 3 only.;   Pharmacokinetics: measure of plasma colistimethate sodium, colistin A, and colistin B levels at multiple time points. Parameters: Cmax, AUC 0-t, Tmax, T1/2, Kel, clearance. Cohort 4 only.;   Pharmacokinetic effect of colistimethate sodium: measure of bronchoalveolar lavage (BAL) colistimethate sodium, colistin A, and colistin B levels.
15 Recruiting Connecting Resources for Urban Sexual Health
Conditions: HIV;   Sexually Transmitted Infections
Interventions: Other: Testing and linkage to care for Y/MSM;   Behavioral: Engagement and retention for HIV-positive Y/MSM in care;   Other: Engagement and retention for HIV-negative Y/MSM in sexual health services;   Drug: Stribild PEP Substudy
Outcome Measures: The proportion of young men who have sex with men (YMSM) of color who test positive for HIV at partner agencies and the proportion of positive and negative YMSM who are tested for HIV and linked to care on a quarterly and annual basis.;   The proportion of HIV-positive enrolled YMSM who are retained, on therapy, and who have achieved viral suppression within one year of entering care.;   The proportion of HIV-uninfected YMSM participants who are retained, receive sexually transmitted infection (STI) testing, and receive non-occupational post-exposure-prophylaxis (nPEP) and/or PrEP.;   Substudy Primary Outcome: To evaluate the tolerability and acceptability of a 28 day course of Stribild® given as post-exposure prophylaxis (PEP) to prevent sexual acquisition of HIV-1.;   Substudy Secondary Outcome: To assess the renal safety of Stribild® PEP.;   Substudy Secondary Outcome: To document any HIV-1 seroconversions occurring while on Stribild® PEP.;   Substudy Secondary Outcome: To document the side effect profile of Stribild® given as PEP;   Substudy Secondary Outcome: To assess adherence to Stribild® PEP.
16 Not yet recruiting A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64
Conditions: Neonatal Early-onset Sepsis;   Neonatal Late-onset Sepsis
Intervention: Other: Stoppage of antibiotics at 24h vs. continuing antibiotics for 48h, randomization based on neutrophil CD64 values.
Outcome Measures: Number of infants with early-onset sepsis (EOS) and late-onset sepsis (LOS) randomized to either stopping or continuing antibiotics at 24h, based on the neutrophil CD64 measurement;   Change in the Neutrophil CD64 Index value in neonates with/without exposure to antibiotics from 24h to 48h.
17 Not yet recruiting Wood Stove Interventions and Child Respiratory Health
Condition: Lower Tract Respiratory Infection
Interventions: Behavioral: Education Intervention (Tx1);   Device: Air Filtration Unit Treatment (Tx2);   Device: Placebo Intervention (Tx3)
Outcome Measures: Lower respiratory tract infection;   Particulate matter exposure reduction
18 Not yet recruiting Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India
Condition: HIV Infection
Intervention: Drug: Truvada
Outcome Measures: Sustained uptake and adherence to oral PrEP among female sex workers;   Identification of female sex workers willing to take PrEP;   Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers;   Effective delivery of oral HIV PrEP demonstrated in context of National Targeted Interventions
19 Recruiting Procalcitonin Antibiotic Consensus Trial (ProACT)
Condition: Lower Respiratory Tract Infection (LRTI)
Interventions: Other: Procalcitonin level;   Other: Results of procalcitonin (PCT) level to treating clinician;   Other: Provide procalcitonin guideline to treating clinician;   Other: Telephone Visit
Outcome Measures: Total antibiotic exposure days;   Combined endpoint of adverse outcomes that could be attributable to withholding antibiotics in LRTI;   Rate of antibiotic initiation by the initial ED clinician
20 Recruiting The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
Condition: HIV-1 Infection
Intervention: Drug: Vorinostat
Outcome Measures: To compare RCVL in HIV-infected patients on stable ART, before and after a single exposure to VOR, after a pair of exposures to VOR, and after multiple exposures to VOR.;   To compare the change in HIV RNA expression per million resting CD4 + cells after multiple (10) VOR doses.;   Changes on plasma HIV-1 RNA;   To assess safety, tolerability, and PK profile of VOR;   To assess the alterations in global histone acetylation within resting lymphocytes;   To compare the frequency of resting CD4+ T cell infection (RCI) after multiple (10) repeated short interval dosing with VOR

These studies may lead to new treatments and are adding insight into Exposure To Communicable Disease etiology and treatment.

A major focus of Exposure To Communicable Disease research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Exposure To Communicable Disease